Media OutReach
Counterfeit and Refurbished Transducers Pose Serious Safety Risks
Merz Aesthetics® Hong Kong Launches Ultherapy® Authenticity Verification Reward Program This August Consumers Urged to Verify Ultherapy® Transducers Authenticity for Safe and Effective Treatments
HONG KONG SAR & MACAU SAR – Media OutReach Newswire – 30 June 2025 – Merz Aesthetics®, the world’s largest dedicated medical aesthetics business for more than 115 years, leads the industry shift with Ultherapy PRIME®, the latest innovation in hyper-personalized, non-invasive skin lifting., which have earned the trust and support of medical aesthetics professionals and consumers in Hong Kong and Macau. Recently, the emergence of counterfeit and refurbished transducers in the local markets pose serious potential risks to treatment results and patients’ safety. Merz Aesthetics® Hong Kong urges consumers to verify the authenticity of Ultherapy® products and seek treatments exclusively at authorized clinics. Merz Aesthetics® Hong Kong will launch the Ultherapy® Authenticity Verification Reward Program this August — making it easy for consumers to verify the Systems and transducers, reinforcing confidence and safety in every treatment.
Trusted Technology, Proven Results — Beware of Counterfeit Transducers
Ultherapy® and its latest innovation, Ultherapy PRIME® (collectively “Systems”), are manufactured in the United States and remain the only US FDA cleared non-invasive micro-focused ultrasound skin lifting treatment with real-time visualization.. Ultherapy® DeepSEE® transducers are available in 4.5mm, 3.0mm, and 1.5mm depths to target different layers of the skin. The real-time imaging allows practitioners to visualize skin structure and tissue layers during treatment, ensuring that energy is precisely delivered to the intended depth of the skin for safe and effective results. Each Ultherapy® DeepSEE® transducer is designed to deliver a designated 2,400 dosage lines and cannot be recharged or refurbished once depleted.
The recent emergence of counterfeit or refurbished transducers in the market has raised serious concerns over treatment results and patients’ safety. Inaccurate energy delivery into the skin will compromise lifting results and create extremely high risks, potentially leading to burns. The use of counterfeit or refurbished transducers can also impair the Systems, potentially leading to unpredictable outcomes that may cause harm to patients.
Authentic Transducers Are Traceable — Counterfeit Unknown
Every Ulthera® DeepSEE® transducers carries a unique serial number and QR code, allowing it to be traced back to the purchasing clinic. Counterfeit or refurbished transducers often fail QR verification, raising questions about their origin and posing significant safety risks. In addition, every authentic transducer has a specified shelf-life which is12 months from the date of manufacture. Expired transducers should not be used, as they may result in unpredictable outcomes which can possibly harm or injure the patients because there is no clinical evidence to support the use of such expired transducers.
Choose Only Authorized Ultherapy® Clinics
Our official Ultherapy® website (www.ultherapy.com.hk) regularly updates the list of clinics and medical aesthetic centers that use authentic Systems and transducers. Each authorized provider receives official certificates for in-clinic display.
Merz Aesthetics® urges consumers to choose authentic Ultherapy® treatments from officially authorized clinics and aesthetic centers to ensure that only certified Systems and transducers are used. Products obtained through unauthorized or parallel import channels may not comply with the manufacturer’s prescribed storage and handling standards, potentially compromising safety and efficacy.
3-Step Verification Program Launches This August
To help consumers easily identify authentic Systems and transducers, Merz Aesthetics® Hong Kong is launching the Ultherapy® Authenticity Verification Reward Program in August 2025. With just three simple steps, consumers can authenticate products and enjoy a special reward:
1. Scan the QR code on the System to verify authenticity. Counterfeit machines typically lack valid QR verification.
2. Take a photo of the QR code on the transducer and upload it to the official website for instant verification.
3. Successfully complete both verifications to receive a HK$100 Häagen-Dazs coupon as your reward (limited quantities, available in Hong Kong only).
Report Suspected Counterfeit or Refurbished Devices
Merz Aesthetics® Hong Kong will continue to take enforcement action against the sale or use of counterfeit version of the Ultherapy® and Ultherapy PRIME® systems, as well as unauthorized, refurbished, or counterfeit transducers. The company also warns against any unauthorized modifications or repairs of the Systems. Only authorized representatives and service centers, certified by the manufacturer, are properly trained and qualified to inspect, repair, or replace components of the Systems.
Merz Aesthetics® Hong Kong believes that the patients’ well-being and treatments safety are core values shared with its network of professional medical partners. We urge both providers and consumers to report any suspected use of counterfeit systems, counterfeit transducers, or refurbished transducers.
Consumers are encouraged to consult the official Ultherapy® website (www.ultherapy.com.hk) for a list of authorized clinics before treatment. With the launch of the Ultherapy® Authenticity Verification Reward Program this August 2025, they can also complete a simple verification process to confirm that both the Systems and transducers are authentic ensuring every session is safe, effective, and provides piece of mind.
Hashtag: #MerzAesthetics
The issuer is solely responsible for the content of this announcement.
About Ultherapy® /Ultherapy PRIME®
Ultherapy® , The noninvasive Ultherapy® procedure is U.S. FDA-cleared to lift skin on the neck, on the eyebrow and under the chin as well as to improve lines and wrinkles on the décolletage, with over 3 million treatments performed worldwide. Using micro-focused ultrasound energy with real-time visualization (MFU-V), Ultherapy® can see deep within the layers of the skin and enable treatment plan to be hyper-personalized. A single treatment provides results lasting up to one year with no downtime.1,2,3,4,5,6,7.
Ultherapy PRIME® is the latest innovation version of Ultherapy®, recognized as the gold standard for non-surgical lifting and skin tightening.
Learn more about Ultherapy® treatments at 
www.ultherapy.com.hk
About Merz Aesthetics®
Merz Aesthetics® is a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves — however they define it. Clinically proven, its product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with high standards of safety and efficacy. Being family owned for more than 115 years, Merz Aesthetics® is known for building unique connections with customers who feel like family. Merz Aesthetics®’ global headquarters is in Raleigh, N.C., USA, with a commercial presence in 90 countries worldwide. It is also a part of Merz Group, which was founded in 1908 and is based in Frankfurt, Germany. Learn more at https://www.merzaesthetics.com.hk/
References:
1. Ulthera® Instructions for Use.Fabi SG, Joseph J, Sevi J, Green JB, Peterson JD. Optimizing patient outcomes by customizing treatment with microfocused ultrasound with visualization: gold standard consensus guidelines from an expert panel. J Drugs Dermatol. 2019;18(5):426-432.
2. Park JY, et al. Customized Treatment Using Microfocused Ultrasound with Visualization for Optimized Patient Outcomes: A Review of Skin tightening Energy Technologies and a Pan-Asian Adaptation of the Expert Panel’s Gold Standard Consensus. J Clin Aesthet Dermatol. 2021;14(5): E70-E79.
3. Werschler WP, Werschler PS. Long-term efficacy of micro-focused ultrasound with visualization for lifting and tightening lax facial and neck skin using a customized vectoring treatment method. J Clin Aesthet Dermatol. 2016;9(2):27-33.
4. Goldie K, Kerscher M, Fabi SG, Hirano C, Landau M, Lim TS, Woolery-Lloyd H, Mariwalla K, Park JY, Yutskovskaya Y. Skin Quality – A Holistic 360° View: Consensus Results. Clin Cosmet Investig Dermatol. 2021 Jun 14;14:643-654. doi: 10.2147/CCID.S309374. PMID: 34163203; PMCID: PMC8214518.
5. Sasaki G, Grossman J, Fabi SG, et al. Stimulation of Collagen Synthesis in Human Skin Following Microfocused Ultrasound Therapy. Presented at the ASDS 2018 Annual Meeting.
6. White WM, Makin IR, Barthe PG, Slayton MN, Gliklich RE. Selective creation of thermal injury zones in the superficial musculoaponeurotic system using intense ultrasound therapy: a new target for non-invasive facial rejuvenation. Arch Facial Plast Surg. 2007;9(1):22-29.
7. Data on File.
Media OutReach
Marriott’s 2025 Cage-Free Pledge in the Spotlight as Field Visit Raises Animal Welfare and Hygiene Concerns
Field visit finds dead birds, eggs surrounded by faeces and fly infestations at egg farm whose operators claim to supply Marriott properties
- Eggs stored directly on the floor, surrounded by dirt, feathers and excrement
- Swarms of flies around birds and their food
- Accumulated faeces on and underneath cages
- Dead birds discarded around the facility
- Birds with severe eye injuries or blindness
- Birds crammed into dirty wire cages
- Poor access to water
Hashtag: #HelpMarriottFindAsia #AnimalWelfare #CorporateAccountability #EthicalSourcing #FoodSafety
The issuer is solely responsible for the content of this announcement.
About INCAF
The Indonesia Network for Compassionate Animal Farming works to advance corporate accountability for animal welfare in Indonesia, driving transparency and progress toward cage-free supply chains. Visit 
https://incaf.org
Media OutReach
Linklogis Releases 2025 Annual Results: Total Volume of Processed Supply Chain Assets Exceeds RMB500 Billion, Unveiling the “SC+ Platform”
In addition, Linklogis has always placed shareholder interests at the core of its corporate governance, rewarding investors’ trust through sustained and tangible actions. In August 2025, the Board approved a new share repurchase program of no less than US$80 million to be implemented over a one-year period. Under this repurchase program, the company has cumulatively repurchased shares totaling HK$365 million (approximately US$47 million), demonstrating its confidence in its long-term value through concrete actions.
Focusing on Core Business, Accelerating Business Structure Optimization
In 2025, Linklogis remained focused on its core business and accelerated the optimization of its business structure. The total volume of supply chain assets processed by its technology solutions reached RMB508.1 billion, up 27% year-on-year. With a market share of 22%, the company ranked first in the industry for the sixth consecutive year. The number of anchor enterprises served increased to 3,145, including 54 of China’s Top 100 enterprises and 151 of China’s Top 500 enterprises, while the number of financial institution partners reached 428, further improving the efficiency of industry-finance collaboration.
Linklogis’ supply chain finance technology solutions include Anchor Cloud, which consists of Multi-tier Transfer Cloud, AMS Cloud and Treasury Cloud, as well as FI Cloud, which consists of ABS Cloud and eChain Cloud. In 2025, the total volume of supply chain assets processed by Anchor Cloud reached RMB369.6 billion, representing a year-on-year increase of 31%. The total volume of supply chain assets processed by Multi-tier Transfer Cloud reached RMB304.2 billion, surging 47% year-on-year, with its contribution to the group’s total asset volume rising from 52% in 2024 to 60% in 2025. The total volume of supply chain assets processed by AMS Cloud, however, was RMB65.4 billion, down 13% year-on-year due to the continued decline in issuance volume in the supply chain asset securitization market.
The total volume of supply chain assets processed by FI Cloud reached RMB128.9 billion, up 20% year-on-year. Both ABS Cloud and eChain Cloud recorded solid double-digit growth in transaction volume, contributing to a 25% year-on-year increase in FI Cloud revenue. In the ABS Cloud segment, the total volume of supply chain assets processed reached RMB69.1 billion, rising 28% year-on-year. In the eChain Cloud segment, the total volume of supply chain assets processed reached RMB59.7 billion, increasing 13% year-on-year.
Linklogis focused on six key industries, including infrastructure and construction, new energy and advanced manufacturing, and worked with its subsidiary Bytter Technology to deepen targeted cross-selling, achieving breakthroughs in high-quality customer acquisition. Leveraging its one-stop comprehensive industrial-finance solutions and innovative scenario-based applications, Linklogis worked with a number of central and state-owned enterprises and leading private enterprises, including Shougang Group, China Coal Mine Construction Group Corporation and JA Solar Technology, to launch integrated industrial-finance platform projects. At the same time, it provided targeted support to 17 high-quality enterprises, including Shanghai Construction Group, Yunnan Construction and Investment Holding Group and Luzhou Laojiao, covering scenarios such as order financing, bill collateral, and supply chain bill transfer, supporting coordinated growth in both scale and value creation.
Building the “Second Growth Curve”, Unlocking Global Trade Finance Potential
2025 marked a pivotal year for Linklogis’ international business as the company embarked on a new chapter and accelerated the development of its “second growth curve.” During the year, Linklogis officially launched a comprehensive rebranding of its international business, introducing “Unloq” as its new identity for the global market, reflecting its vision of unlocking the potential and efficiency of global trade finance. Guided by a core strategy centered on cross-border trade corridors, scenario-based finance and technology-driven risk management, Unloq is committed to building a globally connected digital supply chain finance platform with strong local execution capabilities.
In line with its core strategy, the company has leveraged its cloud-native technology to launch the innovative “SC+ Platform”, designed to connect global real-world trade with digital finance. The “SC+” signifies its core function of connecting smart contracts with compliant digital payment instruments, forming a technology-enabled solution for global trade finance. The platform is dedicated to building the next-generation digital infrastructure for global trade finance and addressing systemic challenges in cross-border trade, including credit verification, fund turnover, and clearing and settlement efficiency. Through the platform, funders can utilize various compliant payment methods to purchase trade receivables.
To date, Unloq has completed the deployment of the core architecture of the SC+ Platform. Working with multiple commercial partners, Unloq has advanced the rollout of innovative applications leveraging compliant digital payment methods. In 2025, Linklogis successfully secured the bid for a Web3.0-based supply chain finance platform project for a leading central state-owned enterprise, marking a new milestone in its technological capabilities and industry recognition in the field of digital trade infrastructure.
In its international business, Unloq accelerated the expansion of cross-border trade services. In addition to traditional B2B goods trade, cross-border e-commerce and online travel agencies, it also expanded into cross-border logistics, bringing the total number of platform customers to 1,550, representing a net year-on-year increase of 451. With the deeper penetration of the SC+ Platform in cross-border trade finance, the continued expansion of its global localized service network, and the accelerated integration of solutions supporting Chinese enterprises’ overseas expansion, Linklogis’ cross-border and international business is expected to enter a phase of exponential growth in both asset volume and revenue in 2026, embarking on a new chapter of high-quality and sustainable development.
Advancing the “AI-powered Industrial Finance” Strategy: From Internal Empowerment to Industry Value Co-Creation
Linklogis remains committed to its “AI-powered Industrial Finance” strategy and continues to promote the deep integration of AI with supply chain finance across the entire value chain. Built on years of technological expertise and scenario-based refinement, its AI capabilities have evolved from internal productivity tools into a sophisticated intelligence engine that empowers the entire industrial ecosystem. By deeply integrating leading domestic large language models with its proprietary supply chain finance scenario knowledge graph and multimodal business elements, the company has systematically advanced the ongoing iteration and capability enhancement of its self-developed vertical model, LDP-GPT. Building on this foundation, Linklogis has developed the “BeeLink AI Agent” product matrix, covering more than ten core scenarios including intelligent trade document checking, intelligent PBOC registration, intelligent KYC, and intelligent risk management.
In 2025, BeeLink AI Agent continued to deliver breakthroughs in market penetration and commercialization. The number of customers served rose to 42, including domestic and overseas financial institutions and industry leaders such as Standard Chartered Bank, Bank of Hangzhou, and China Electrical Equipment Finance. Processing efficiency improved by 20 times, while accuracy in key processes reached 99%. As AI continues to evolve toward an agent-based paradigm, Linklogis will take “AI Agent+” as a strategic lever to comprehensively upgrade BeeLink AI Agent from functional tools to intelligent collaboration. It will prioritize breakthroughs in advanced capabilities such as cross-system task coordination, natural-language interactive decision-making, and adaptive workflow optimization, enabling customers to move from point intelligence to enterprise-wide intelligence, and from business insights to intelligent decision-making, thereby delivering end-to-end value across the entire value chain.
Linklogis actively responded to China’s “dual carbon” strategy and high-quality development agenda by embedding ESG principles into product innovation and the entire service lifecycle, leveraging technology to advance green finance, inclusive finance, and sustainable development. In 2025, the volume of sustainable supply chain assets served by the company exceeded RMB66.8 billion, representing a year-on-year increase of 80%, with its share of total serviced assets rising from 9% in 2024 to 13% in 2025. During the year, SMEs that obtained financing through Linklogis Supply Chain Multi-tier AR Transfer Platform benefited from an average financing cost of only 2.85%. The company continued to deepen its presence in four key sectors—renewable energy, rural revitalization, environmental protection, and public health—while further expanding into sustainable sectors such as the new energy vehicle supply chain, green buildings, and the circular economy. Through these initiatives, it directed financial resources more precisely to key segments that generate both green and low-carbon benefits and strong social impact, gradually building a broader and more influential sustainable development ecosystem that integrates industry and finance.
Expanding Full-scenario Deployment, Enhancing the Smart Industrial Finance Treasury Product Matrix
Through the acquisition of Bytter Technology, Linklogis made a strategic entry into the corporate treasury management sector. By synergizing management teams and business operations, the company successfully established the Treasury Cloud product line, providing diverse customers with end-to-end treasury management services covering settlement operations, cash planning, financing management, risk monitoring, and intelligent decision-making. As a key component of Linklogis’ “Smart Industrial Finance Treasury” strategy, Treasury Cloud is anchored by a dual-engine approach powered by AI and data, and has established a comprehensive product matrix, including the F1 treasury management system and T6 cash management system for anchor enterprises, the bank treasury system for financial institutions, and the Yingzilian SaaS platform for SMEs.
Since September 11, 2025, Bytter Technology has been consolidated into the group’s financial statements. The integration of the Treasury Cloud business has been fully completed. Linklogis will continue to deepen resources integration and business collaboration between Treasury Cloud and the group’s other supply chain finance technology businesses in areas such as product R&D, channel expansion and customer service. The company will accelerate the development of an integrated, intelligent and scalable Smart Industrial Finance Treasury platform, providing customers with one-stop digital solutions covering treasury management and industrial-finance collaboration.
Charles Song, founder, Chairman and CEO of Linklogis, said: “The year 2026 marks the tenth anniversary of Linklogis. As we stand at the threshold of a new decade, we will remain firmly committed to a core strategy of being technology-driven and globally connected, while steadfastly advancing our dual-engine approach of deepening domestic industrial finance and expanding global digital trade. We will seize opportunities amid transformation and strengthen our competitive advantages through innovation. In the domestic market, we will continue to advance the “AI-powered Industrial Finance” strategy. Anchored by the comprehensive upgrade of BeeLink AI Agent, we will accelerate AI’s evolution from scenario-based enablement to ecosystem-level collaboration. At the same time, leveraging our full-stack capabilities in Smart Industrial Finance Treasury solutions, we will continue to refine our integrated one-stop solutions, consolidate our market leadership, and ensure the steady growth of our core business. In international markets, we will accelerate the expansion of global cross-border digital trade networks through Unloq and roll out the SC+ Platform along key global trade corridors. We aim to become a key builder and connector in the ongoing digital and intelligent transformation of global trade finance. The future is already unfolding. Only the adaptable can prevail, and only the persistent can go the distance. With technology as our oar and industry as our vessel, Linklogis will continue to join forces with our partners, embarking together on the magnificent journey toward a digital and intelligent future for global industrial finance.”
Hashtag: #Linklogis
The issuer is solely responsible for the content of this announcement.
Media OutReach
CK Life Sciences’ Sequencio Therapeutics Presents the Latest Vaccine Research Advancements at the American Association for Cancer Research Annual Meeting
These presentations mark Sequencio’s first major scientific unveiling since its formation and showcase significant advancements in next‑generation cancer vaccine technologies based on Sequencio’s proprietary TrueHLA™ Epitope‑to‑Efficacy™ translational design framework, which enables rational, data‑driven vaccine development across circRNA, mRNA, peptide, and protein‑based platforms.
Collectively, Sequencio’s five AACR 2026 presentations highlight a consistent theme: rationally designed cancer vaccines that demonstrate robust immunogenicity and compelling anti‑tumour activity across multiple targets and modalities in preclinical models. These data underscore the strength of Sequencio’s approach to translating antigen selection into functional immune responses and tumour control. Building on this foundation, Sequencio is prioritizing its most promising programs for IND‑enabling studies, with the goal of accelerating select vaccine candidates into early‑stage clinical development through strategic partnerships and global collaboration.
Dr Melvin Toh, Vice President & Chief Scientific Officer of CK Life Sciences, expressed, “Sequencio’s cancer vaccine pipeline continues to advance with strong momentum. Our AACR 2026 presentations underscore both the scientific promise of our vaccines and the disciplined execution driving their progress. We look forward to building on this foundation as we advance next‑generation immunotherapies for patients.”
The AACR Annual Meeting is a gathering central to the global cancer research community, bringing together scientists, clinicians, other healthcare professionals, survivors, patients and advocates every year to share the latest breakthroughs and developments in cancer science and medicine. Last year, the 2025 Annual Meeting attracted 22,100 in-person participants from 85 countries.
Scientific Poster Presentations by Sequencio Therapeutics at AACR 2026
All five posters will be presented on 21 April 2026.
1. p53 Modified Shared Neoantigen Vaccine (Poster Number: 4361)
Title: Single amino acid residue substitution to improve immunogenicity of HLA peptides targeting p53 neoantigen
Authors: Chi Han Samson Li, Hong Wang, Kin Tak Chan, Genwei Zhang, Zhenghui Wang, Lipeng Lai, Melvin Toh
2. IGF1R Cancer Vaccine (Poster Number: 4368)
Title: Vaccine targeting IGF1R induces neutralizing antibody and robust anti‑tumor activity in a syngeneic mouse colon cancer model
Authors: Kenneth Nansheng Lin, Melvin Toh, Hong Wang
3. B7‑H3 Cancer Vaccine (Poster Number: 4369)
Title: B7-H3 vaccine induces robust humoral and cellular immunity and inhibits tumor growth in mice
Authors: Kenneth Nansheng Lin, Melvin Toh, Hong Wang
4. TROP2 circRNA + IL‑7 Combination Vaccine (Poster Number: 4370)
Title: TROP2‑circular RNA vaccine and IL7 synergistically inhibit TROP2+ tumor growth in mouse models
Authors: Zirong He, Yanan Li, Antong Li, Xiaoxuan Liu, Kenneth Nansheng Lin, Fan Yan Meng, Melvin Toh, Hong Wang
5. Claudin‑6 Cancer Vaccine (Poster Number: 4375)
Title: Claudin 6 vaccines effectively inhibit tumor growth in a syngeneic mouse colon cancer model
Authors: Na Wang, Lam Chow, Melvin Toh, Hong Wang
Hashtag: #CKLifeSciences #Sequencio #CancerVaccines #R&D #Pharmaceutical #AACR
The issuer is solely responsible for the content of this announcement.
CK Life Sciences Int’l., (Holdings) Inc.
CK Life Sciences Int’l., (Holdings) Inc. (stock code: 0775) is listed on the Stock Exchange of Hong Kong. With a mission of improving the quality of life, CK Life Sciences is engaged in healthcare research and development, with operating businesses that enable its R&D sustainability. Regarding pharmaceutical research and development, CK Life Sciences’ operations are focused on conducting research and development into cancer vaccines, RNA therapeutics and pain management solutions. CK Life Sciences is a member of the CK Hutchison Group. For additional information, please visit www.ck-lifesciences.com.
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism10 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking8 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn